WEBULL
News
MNPR
75.12
+0.69%
0.52
Weekly Report: what happened at MNPR last week (1208-1212)?
Weekly Report · 23h ago
Weekly Report: what happened at MNPR last week (1201-1205)?
Weekly Report · 12/08 10:37
Weekly Report: what happened at MNPR last week (1124-1128)?
Weekly Report · 12/01 10:32
Weekly Report: what happened at MNPR last week (1117-1121)?
Weekly Report · 11/24 10:37
Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
TipRanks · 11/18 18:45
Weekly Report: what happened at MNPR last week (1110-1114)?
Weekly Report · 11/17 10:38
Oppenheimer Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)
TipRanks · 11/14 12:55
MONOPAR THERAPEUTICS INC <MNPR.O>: RAYMOND JAMES CUTS TO OUTPERFORM FROM STRONG BUY; CUTS TARGET PRICE TO $123 FROM $142
Reuters · 11/14 12:22
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Benzinga · 11/14 12:10
Monopar Therapeutics Cut to Outperform From Strong Buy by Raymond James
Dow Jones · 11/14 12:04
Monopar Therapeutics Price Target Cut to $123.00/Share From $142.00 by Raymond James
Dow Jones · 11/14 12:04
Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123
Benzinga · 11/14 11:54
Monopar Therapeutics Inc (MNPR) Gets a Buy from H.C. Wainwright
TipRanks · 11/14 11:37
BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)
TipRanks · 11/14 11:17
Monopar downgraded to Outperform from Strong Buy at Raymond James
TipRanks · 11/14 11:11
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05
Seeking Alpha · 11/14 10:15
U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66
Reuters · 11/14 09:48
Monopar Therapeutics Inc (MNPR) Gets a Buy from Barclays
TipRanks · 11/14 09:06
Monopar Therapeutics Reports Increased Cash Reserves Amid Losses
TipRanks · 11/14 04:46
Monopar Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 11/13 21:25
More
Webull provides a variety of real-time MNPR stock news. You can receive the latest news about Monopar Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.